Therefore, we showed that the treatment with (Bu2Sn)2TPPS (Figure 3A–C, left and right panels) and with (Bu3Sn)4TPPS (Figure 3A–C, middle and right panels), led to a significant increase of the full-length form of PARP-1 that is more evident in A375 and HT-144 melanoma cells treated with (Bu3Sn)4TPPS (Figure 3A,B, middle and right panels), but do not induce the cleavage of PARP-1 in treated melanoma cells (Figure 3A–C). This evidence concerns the gene PARP1 and melanoma.